Search
Rheumatoid Arthritis Clinical Trials in Cleveland, OH
A listing of 5 Rheumatoid Arthritis clinical trials in Cleveland, OH actively recruiting volunteers for paid trials and research studies in various therapeutic areas.
1 - 5 of 5
The city of Cleveland, Ohio, currently has 5 active clinical trials seeking participants for Rheumatoid Arthritis research studies.
Featured Trial
Cardiovascular Disease Clinical Study
Recruiting
A clinical study for people that suffer with Cardiovascular Disease
Conditions:
Cardiovascular Disease
Featured Trial
ASCVD A Clinical Study
Recruiting
A clinical study for people that suffer with ASCVD
Conditions:
ASCVD A
ASCVD
Atherosclerotic Cardiovascular Disease (ASCVD)
Atherosclerotic Cardiovascular Disease
Atherosclerotic Cardiovascular Diseases
Featured Trial
ASCVD B Clinical Study
Recruiting
A clinical study for people that suffer with ASCVD
Conditions:
ASCVD B
ASCVD
Atherosclerotic Cardiovascular Disease
Atherosclerotic Cardiovascular Disease (ASCVD)
Atherosclerotic Cardiovascular Diseases
Featured Trial
Paid Clinical Studies Nationwide
Recruiting
Nationwide clinical trials offered in your area. Some trials offering up to several thousand dollars in compensation for participation.
Featured Trial
Healthy Participants Needed (Colonoscopy + Cancer Screening)
Recruiting
Earn $325 - $475 in electronic payment card compensation for your time and effort by participating in a clinical study to develop a blood test that may one day help screen for colon cancer. Take a quick quiz to see if you qualify.
Conditions:
Healthy
Healthy Volunteers
Healthy Subjects
Healthy Volunteer
Healthy Participants
Featured Offer
Lose Weight with GLP-1 Medications
Recruiting
Policy Lab has partnered with OnlineSemaglutide.org to offer trusted access to semaglutide and other GLP-1 medications, including generic alternatives to Ozempic® and Wegovy®.
GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.
As a valued user, you’re eligible for $50 off your first program with code policy-lab-50.
GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.
As a valued user, you’re eligible for $50 off your first program with code policy-lab-50.
Conditions:
Overweight
Overweight and Obesity
Obesity
Weight Loss
Morbid Obesity
A Study of CC-97540, CD-19-Targeted Nex-T CAR T Cells, in Participants With Severe, Refractory Autoimmune Diseases (Breakfree-1)
Recruiting
The purpose of this study is to establish the tolerability, preliminary efficacy, and pharmacokinetics of CC-97540 in participants with severe, refractory autoimmune diseases (Breakfree-1).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/08/2025
Locations: Cleveland Clinic, Cleveland, Ohio
Conditions: Systemic Lupus Erythematosus, Idiopathic Inflammatory Myopathy, Systemic Sclerosis, Rheumatoid Arthritis
A Phase 2a Master Protocol Assessing Inebilizumab and Blinatumomab in Autoimmune Diseases
Recruiting
The main objective is to assess the safety and tolerability of inebilizumab in adult participants with active and refractory systemic lupus erythematosus (SLE) with nephritis (Subprotocol A) and to assess the safety and tolerability of subcutaneous (SC) blinatumomab in adult participants with active and refractory SLE with nephritis (Subprotocol B) and in adult participants with active refractory rheumatoid arthritis (RA) (Subprotocol C).
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
08/06/2025
Locations: MetroHealth Medical Center, Cleveland, Ohio
Conditions: Systemic Lupus Erythematosus, Active Refractory Rheumatoid Arthritis
RA-PRO PRAGMATIC TRIAL
Recruiting
The 2021 ACR RA treatment guideline, based on widely acknowledged low to moderate quality evidence, recommends switching to a non-tumor necrosis factor (TNFi) biologic (choose among existing medications, currently, rituximab, abatacept, tocilizumab, or sarilumab) or a targeted synthetic DMARD arm (tsDMARD; choose among existing medications, currently, tofacitinib, baricitinib, upadacitinib) in patients with active RA despite the use of a TNFi-biologic. In practice, most patients receive another... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/15/2025
Locations: University Hospital Cleveland Medical Ctr, Cleveland, Ohio +1 locations
Conditions: Rheumatoid Arthritis
Shoulder iD™ Primary Reversed Glenoid Outcomes Clinical Study
Recruiting
The goal of the Shoulder iD™ Primary Reversed Glenoid Outcomes Clinical Study is to collect safety and performance data on the commercially available Shoulder iD™ Primary Reversed Glenoid device. The study will learn about standard device use in adult patients who have a functional deltoid muscle and massive and non-repairable rotator cuff tear. The main questions it aims to answer are:
* What is the average improvement in patient-reported shoulder function after 2 years when compared to before... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/22/2025
Locations: Cleveland Clinic, Cleveland, Ohio
Conditions: Rotator Cuff Tears, Rheumatoid Arthritis Shoulder, Osteoarthritis Shoulder, Avascular Necrosis of the Head of Humerus, Fracture, Humeral, Traumatic Arthritis of Right Shoulder Region (Diagnosis), Shoulder Deformity
Persona OsseoTi Keel Compatibility Study (Total Knee Arthroplasty)
Recruiting
The main objective of the study is to evaluate the safety, performance and clinical benefits of the Persona implant and its instrumentation in primary total knee arthroplasty
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/29/2025
Locations: Cleveland Clinic, Cleveland, Ohio
Conditions: Knee Pain Chronic, Osteoarthritis, Knee, Rheumatoid Arthritis, Traumatic Arthritis, Polyarthritis, Varus Deformity, Valgus Deformity, Flexion Deformity of Knee, Avascular Necrosis
1 - 5 of 5
